The Flow Cytometry and Cellular imaging Facility (FCCIF) was established to provide access to state-of-the art cell analysis technology for MD Anderson investigators, and provides cell sorting, analytical flow cytometry, cellular imaging and custom monoclonal antibody (mAb) conjugations to its users. The Core provides researchers with technical expertise in instrument operation, assay development, data acquisition and various analysis techniques. Analytical flow cytometry is an indispensable tool for the study of all aspects of cell biology, including protein expression, cell proliferation and differentiation, cell signaling pathways, enzyme activity, gene regulation, ceil lineage, apoptosis, autophagy and chemotherapeutic resistance. The Core has recently acquired a DVS CyTOF Mass Cytometer, enabling the detection and characterization of up to 100 molecular markers at the single cell level. This instrument represents a transformational technology enabling the detection and characterization of rare and mixed cell populations on the single cell level. Cell sorting. Cell isolation for culture and further characterization is performed via droplet-based sorting, which isolates a wide variety of cells based on combinations of antibody-based stains, fluorescent protein expression, and viability indicators. Imaging. The Core offers researchers tools and techniques for image acquisition, SD-reconstruction, and time-series observation as well as a variety of image processing and analysis functions via laser scanning cytometry and confocal microscopy and also offers multispectral, epifluorescent, and colorimetric microscopy. Custom mAb conjugations. Antibody conjugation is a new service of the FCCIF that provides conjugates with fluors and tags that are not commercially available. The FCCIF uses 24 major instrument systems supporting the research of-345 investigators who hold 13 POIs, 112 ROIs, and 9 P50 SPOREs. Peer-reviewed investigators account for 94% of the utilization, and 35% of total cost is requested from the CCSG. Over the past 5 years, the FCCIF has performed more than 50,000 hours of service, representing a 125% increase over the prior grant period. Over the past 5 years, the FCCIF has facilitated publication of 408 reports, with 67% in journals with an impact factor >5 and 22% with an impact factor >10. In the future, the FCCIF will continue to develop the use of the current instrumentation, including the DVS Sciences CyTOF, and novel analysis programs, including the SPADE algorithm. Older equipment will be replaced, and an Amnis Image Stream, a Vectra 2 automated multispectral imaging system and single-cell analysis systems such as Fluidigm's BioMark may be added.

Public Health Relevance

The FCCIF constitutes a point of convergence of many research programs, as evidenced by service to 300 principal investigators. Additional services like custom monoclonal antibody conjugations allow MD Anderson researchers to expand the list of identifiable markers both for profiling and for cell sorting. PROJECT/

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
4P30CA016672-41
Application #
9097560
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
41
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, George J (2018) Leveraging Data, the Next Big Advance for Quality Improvement in Colorectal Cancer. Dis Colon Rectum 61:415-416
Rauch, Gaiane M; Kuerer, Henry M; Adrada, Beatriz et al. (2018) Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol 25:1953-1960
Peng, Bo; Wang, Gao; Ma, Jun et al. (2018) SoS Notebook: an interactive multi-language data analysis environment. Bioinformatics 34:3768-3770
Ariza-Heredia, Ella J; Chemaly, Roy F; Shahani, Lokesh R et al. (2018) Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. Transpl Int 31:639-648
Kraft, Ira L; Akshintala, Srivandana; Zhu, Yuelin et al. (2018) Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clin Cancer Res 24:753-765
Rozovski, Uri; Harris, David M; Li, Ping et al. (2018) STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9:21268-21280
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Wang, Jian; Shete, Sanjay (2018) Estimation of indirect effect when the mediator is a censored variable. Stat Methods Med Res 27:3010-3025
Chambers, Mark S; Rugo, Hope S; Litton, Jennifer K et al. (2018) Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc 149:291-298
Echeverria, Gloria V; Powell, Emily; Seth, Sahil et al. (2018) High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun 9:5079

Showing the most recent 10 out of 12418 publications